Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2012

View Archived Issues

Proof-of-concept study begins with gevokizumab in acute coronary syndrome

InSite Vision completes enrollment in phase III BromSite study

Japanese group divulges new antibacterial agents

New hPASK/CK II inhibitors synthesized by Bioenergenix

Researchers at Novartis synthesize new CYP17 inhibitors

New TGR5 receptor agonists prepared by Bristol-Myers Squibb

GDC-0449 evaluated for new indication

Actinium Pharmaceuticals and Philogen begin development of Ac-225 labeled antibody

OPKO Health receives research grants from Mexican government

Priority review awarded for Eisai's NDA for new formulation of AcipHex

Taisho and Novartis sign agreement for diabetes treatment candidate in Japan

Viralytics reports preliminary data from research conducted with University of Surrey

Roche patents novel D3/5-HT2A receptor ligands

University of Sydney discloses novel agents isolated from propolis

New targets identified for malignant peripheral nerve sheath tumors

VR Laboratories selects new rhinovirus therapeutic

Ghent University and MDxHealth establish new epigenomics center

FDA posts Vibativ advisory committee briefing documents

Cytokinetics reports phase IIa tirasemtiv trial data

Lipid-core peptides may have efficacy as helminth vaccines

Experimental gene therapy approaches for the treatment of drug-resistant epilepsy

Cyclin-dependent kinase 6 as a target in medulloblastoma

Novel murine model of proteinuria developed at Washington University

BioCryst Pharmaceuticals and Presidio Pharmaceuticals end merger

Alimera Sciences develops patient access scheme for Iluvien in U.K.

Boston Scientific commences patient enrollment in EVOLVE II trial of Synergy stent system

Cel-Sci updates on phase III Multikine immunotherapy trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...